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Background: Neuroblastoma is a relatively common and highly belligerent childhood tumor with poor prognosis
by current therapeutic approaches. A novel anti-cancer agent of the di-2-pyridylketone thiosemicarbazone series,
namely di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), demonstrates promising anti-tumor activity.
Recently, a second-generation analogue, namely di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone
(DpC), has entered multi-center clinical trials for the treatment of advanced and resistant tumors. The current aim
was to examine if these novel agents were effective against aggressive neuroblastoma in vitro and in vivo and to
assess their mechanism of action.
Methods: Neuroblastoma cancer cells as well as immortalized normal cells were used to assess the efficacy and
selectivity of DpC in vitro. An orthotopic SK-N-LP/Luciferase xenograft model was used in nude mice to assess the
efficacy of DpC in vivo. Apoptosis in tumors was confirmed by Annexin V/PI flow cytometry and H&E staining.
Results: DpC demonstrated more potent cytotoxicity than Dp44mT against neuroblastoma cells in a dose- and
time-dependent manner. DpC significantly increased levels of phosphorylated JNK, neuroglobin, cytoglobin, and
cleaved caspase 3 and 9, while decreasing IkBα levels in vitro. The contribution of JNK, NF-ĸB, and caspase
signaling/activity to the anti-tumor activity of DpC was verified by selective inhibitors of these pathways. After
3 weeks of treatment, tumor growth in mice was significantly (p < 0.05) reduced by DpC (4 mg/kg/day) given
intravenously and the agent was well tolerated. Xenograft tissues showed significantly higher expression of neuroglobin,
cytoglobin, caspase 3, and tumor necrosis factor-α (TNFα) levels and a slight decrease in interleukin-10 (IL-10).
Conclusions: DpC was found to be highly potent against neuroblastoma, demonstrating its potential as a novel
therapeutic for this disease. The ability of DpC to increase TNFα in tumors could also promote the endogenous immune
response to mediate enhanced cancer cell apoptosis.
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The thiosemicarbazone, 3-aminopyridine-2-carboxalde-
hyde thiosemicarbazone (3-AP/Triapine; Fig. 1a), has
undergone over 20 Phase I and Phase II clinical trials
[1]. However, the side effects of this agent have hindered
its clinical application [2]. Based on comprehensive
structure-activity relationship studies [3–6], our team
developed alternative agents of the di-2-pyridylketone
thiosemicarbazone (DpT) class [7, 8] to overcome the
disadvantages of Triapine. The DpT analogues bind iron
and copper to generate oxidative stress in cancer cells,
which induces lysosomal membrane permeabilization
[9–13] and results in these agents overcoming P-
glycoprotein-mediated drug resistance [10, 12, 13]. These
compounds also induce apoptotic and autophagic pathways
[8, 9, 14] and inhibit tumorigenic processes [15–21].
Due to its high efficacy and selectivity, di-2-pyridylketone
4,4-dimethyl-3-thiosemicarbazone (Dp44mT; Fig. 1b) was
chosen as the first lead DpT analogue [7, 8] with its marked
activity being confirmed by others [22–24]. Importantly,
this agent has been demonstrated to upregulate the potent
metastasis suppressor, N-myc downstream-regulated gene-
1 (NDRG1) [25], which inhibits the epithelial to mesenchy-
mal transition [15] and results in suppression of oncogenic
signaling, tumor cell migration [15–21], and metastasis
in vivo [23].
However, due to cardiac fibrosis at high, non-optimal
Dp44mT doses [7], a second generation of DpT ana-
logues was synthesized, resulting in a new lead agent,
namely di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thio-
semicarbazone (DpC; Fig. 1c), that demonstrates high
tolerability [26, 27]. In fact, early in 2016, DpC enteredFig. 1 Line drawings of the structures of a Triapine, b Dp44mT, c DpC,
and d L1multi-center clinical trials for treating advanced tumors
(NCT02688101), which again supports its selectivity,
tolerability, and favorable pharmacological properties
[28]. Significantly, while DpC shares structural similar-
ities to Dp44mT (cf. Fig. 1b, c), it demonstrates a series
of important advantages. These include the following:
(1) DpC, unlike Dp44mT, does not induce cardiac fi-
brosis even when administered at markedly higher
doses [26, 27]; (2) Unlike Dp44mT and Triapine, DpC
does not induce oxyhemoglobin oxidation in vivo [2];
(3) DpC exhibits greater activity than Dp44mT in vivo
against an aggressive human pancreatic tumor xeno-
graft [26]; (4) DpC demonstrated pronounced in vivo
activity after oral and intravenous administration [27],
while Dp44mT was not tolerated orally [29]; and (5) while
both Dp44mT and DpC display appropriate pharmaco-
kinetics, the markedly greater half-life of DpC (t1/2 =
10.7 h for DpC vs. 1.7 h for Dp44mT) further under-
lines its potential [30].
Considering the marked anti-tumor activity of DpC
and its favorable pharmacology and safety profile, it is
notable that it has not yet been examined for the treat-
ment of belligerent neuroblastoma. While the outcomes
of many childhood cancers have improved, advanced
neuroblastoma has a dismal prognosis [31–35]. How-
ever, it is notable that neuroblastoma is sensitive to iron
chelation with standard chelators, such as deferiprone
(L1; Fig. 1d) [36] and desferrioxamine (DFO) alone, or in
combination with cytotoxic chemotherapy [37–41]. This
is despite the fact that DFO and L1 show only low to
moderate anti-tumor activity [36], which is far less
marked than Dp44mT or DpC [7, 8, 26, 27].
In view of the pronounced anti-tumor activity of
Dp44mT and DpC and the sensitivity of neuroblastoma
to iron chelation, this study assessed the activity of these
agents against neuroblastoma in vitro and in vivo with
the aim to investigate the anti-tumor mechanisms in-
volved. The results demonstrate that DpC shows marked
and selective anti-tumor activity, which could be useful
for the treatment of neuroblastoma.
Methods
Cell lines
The human neuroblastoma cell lines, SK-N-LP (provided
by Dr. Nai-Kong Cheung, Memorial Sloan Kettering
Cancer Center, New York, NY, USA), BE(2)C, SK-N-AS,
and SH-SY5Y were purchased from the American Type
Culture Collection (ATCC; Manassas, VA, USA). The
following non-tumorigenic, immortalized normal cell
lines were also used: the human kidney cell line (HK2;
ATCC), human hepatocyte cell line (MIHA; ATCC); the
human bone marrow-derived Tert-immortalized
mesenchymal stem cell line (MSC; from Prof. D.
Campana, St. Jude Children’s Research Hospital,
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cell line (H9C2; from Prof. M. Yang, Nanfang
University, Guangzhou, Guangdong, China).
All neuroblastoma cell lines and the HK2 and MIHA
cells were maintained in Dulbecco’s modified Eagle med-
ium—high glucose (Invitrogen, Grand Island, New York,
NY, USA), supplemented with 100 U/mL penicillin,
100 mg/mL streptomycin (Invitrogen), and 10 % heat-
inactivated fetal bovine serum (Hyclone, Logan, USA).
For the SK-N-LP cell line expressing Luciferase, G418
(1000 μg/mL; Roche, Mannheim, Germany), was added
to the media to maintain selective pressure. The human
MSC line was cultured using Dulbecco’s modified Eagle
medium—low glucose (Invitrogen). All cells were kept
under standard culture conditions at 37 °C in a humidi-
fied 5 % CO2 atmosphere with the culture medium being
renewed every other day. The H9C2 cell type was cul-
tured in culture vessels pre-coated with 0.02 % gelatin
(Difco, Fisher Scientific, Suwanee, GA, USA) and 5 μg/
mL fibronectin (Sigma-Aldrich) solution at 37 °C in a
humidified 5 % CO2 incubator, maintained in Claycomb
media (Sigma-Aldrich) supplemented with 10 % fetal
bovine serum (Sigma-Aldrich), 0.1 mM norepinephrine
(Sigma-Aldrich), 2 mM L-glutamine (Invitrogen), and
penicillin/streptomycin (100 U/mL and 100 μg/mL,
respectively; Invitrogen).
Chemical agents
Both DpC and Dp44mT were synthesized and character-
ized as described previously [27, 42]. Both DpC (5 mg)
and Dp44mT (5 mg) were freshly dissolved in 1 mL
DMSO to generate a 5 mg/mL solution and then diluted
in media for use. On the other hand, L1 (Apotex Inc.,
Toronto, ONT, Canada) was dissolved in doubly distilled
H2O. The cell lines described above were incubated with
either DpC, Dp44mT, or L1 at concentrations of 2.5, 25,
or 250 μM for 0, 12, 24, 48, or 72 h/37 °C.
XTT proliferation assay
Cells were seeded in 96-well plates (approximately 4000
cells/well). After overnight culture, cells were incubated
with either control medium or medium containing DpC,
Dp44mT, or L1. Cellular proliferation was then assessed
after incubations of 24, 48, or 72 h/37 °C using the XTT
kit (Roche). The optical density was measured using a
microplate reader at a wavelength of 450 nm. Cellular
proliferation was demonstrated to be directly correlated
to cell number, as shown for the related MTT assay [4].
In studies using cell signaling pathway inhibitors, cells
were pre-incubated for 2 h/37 °C with 5 μM of the ERK/
MAPK inhibitor, PD98059 (Sigma-Aldrich), 5 μM of the
p38 MAPK inhibitor, SB203580 (Sigma-Aldrich), 5 μM
of the JNK/MAPK inhibitor, SP600125 (Sigma-Aldrich),
15 μg/mL of the NF-kB inhibitor, CAPE (Sigma-Aldrich),and 10 μM of the pan-caspase inhibitor, Z-VAD(ome)-
FMK (Calbiochem, Darmstad, Germany). The viability
of neuroblastoma cells after a 24 h/37 °C incubation
with DpC, Dp44mT, or L1 in the presence or absence
of the inhibitors was examined using the XTT kit, as
described above.
Flow cytometry
Mouse tissues from the tumor, heart, lung, spleen, liver,
kidney, and brain were weighed, homogenized, and fil-
tered using a 70-μm cell strainer on ice. Suspensions
containing approximately 5 × 104 single cells were rap-
idly prepared (within 1 h) to perform flow cytometry.
Cell lines treated with control media alone or this media
in the presence or absence of 1.4 % DMSO or DpC,
Dp44mT, or L1 (all at 25 μM) were also examined using
this technique. The cells that were Annexin V+/PI−,
Annexin V+/PI+, and Annexin V−/PI+ were divided as
either the early apoptosis group, late apoptosis group, or
necrotic group, respectively. The levels of caspase 3 ex-
pression induced by DpC were detected using the FITC
Active Caspase-3 Apoptosis Kit (BD Biosciences, San
Diego, USA). Antibodies against Ngb and Cygb (Abcam,
Cambridge, UK) were kindly provided by Dr. Tan-Un
(School of Professional and Continuing Education, The
University of Hong Kong, Hong Kong, People’s Republic
of China). Data were analyzed by using Flow Jo 8.8.2.
Effect of DpC on the growth of an orthotopic
neuroblastoma in nude mice
Four-week-old male nude mice (BALB/c nu/nu) were ac-
quired from the Laboratory Animal Unit of the University
of Hong Kong with the approval of the Hong Kong
Department of Health and also the Committee for the Use
of Live Animals in Teaching and Research at the
University of Hong Kong (CULATR 3131-13). Mice
were routinely anesthetized and disinfected prior to
the abdominal operation. Using a surgical operation
microscope, 2 × 105 SK-N-LP/Luciferase cells diluted
in 50 % Matrigel® (BD Biosciences) were administered
directly into the fat pad of the left-side adrenal gland
of the mouse. By intraperitoneal injection of luciferin
(Invitrogen), the condition of the xenograft (with a
volume of <4000 mm3) was monitored via a Xenogen
In Vivo Imaging System (Xenogen, CA, USA). The
region of interest (ROI) was generated automatically
and its value was normalized under the luminescence
interval of 17 × 104 to 2.7 × 105.
Two weeks post-neuroblastoma transplantation, the
mice were divided into two groups according to the
tumor ROI value. The mice were then treated with ei-
ther DpC (4 mg/kg) or the vehicle control (i.e., DMSO/
PBS) administered via the tail vein daily for 3 weeks.
Mouse body weight and temperature were recorded
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exceed 10 % at any time (due to ethics requirements at
Hong Kong University). Then, the mice were sacrificed
by an overdose of pentobarbital. Tissues from the tumor,
heart, lung, spleen, liver, kidney, and brain were har-
vested for ex vivo experiments. The length, width, and
height of the tumors were measured using digital cali-
pers to calculate the final xenograft volumes, using the
formula: 4/3 × π (length × width × height)/8.
Histopathology
Approximately 0.5–1 cm3 of mouse tissue taken from the
tumor, heart, lung, spleen, liver, kidney, and brain was
resected and immediately immersed in 4 % paraformalde-
hyde for overnight fixation. The paraffin-embedded blocks
were sectioned and mounted on slides using 4-μm slices.
Then, H&E staining was performed to evaluate histopath-
ology. Pictures were taken using a bright-field microscope
at ×400 magnification.
Western blotting
SK-N-LP cells were lysed directly with radioimmunopre-
cipitation assay (RIPA) buffer for 2 h/4 °C with constant
agitation. Lysates were clarified by centrifugation for
20 min/12,000 rpm/4 °C and the protein concentrations
were quantified using the Bio-Rad Protein Assay Kit
(Bio-Rad, Hercules, CA, USA). SDS-PAGE and western
blotting were performed using standard techniques [43].
The Spectra Multi-Color Protein Ladder (Thermo
Fisher Scientific Inc., New York, NY, USA) was used as
molecular weight markers in gel electrophoresis and
western blotting experiments. The primary rabbit poly-
clonal antibodies of phosphorylated and total ERK, P38
and JNK, caspase 3 (Cell Signaling Technology, Danvers,
MA, USA), neuroglobin, cytoglobin, IkBα (Santa Cruz
Biotechnology, Dallas, TX, USA), as well as mouse
monoclonal antibody against cleaved caspase 9 (Cell Sig-
naling Technology) were used at a dilution of 1:1000 in
PBS-Tween 20 (Bio-Rad) containing 5 % bovine serum
albumin (Sigma-Aldrich).
As an appropriate protein-loading control, a primary
β-actin (CST 4967) antibody at a dilution of 1:8000 was
utilized. Subsequently, a secondary anti-rabbit antibody
at a dilution of 1:4000 was used and the resulting
immune complex visualized by enhanced chemilumines-
cence (Pierce, Chicago, IL, USA). The density of the pro-
tein bands was calculated using Quantity One software
(Bio-Rad).
ELISA assay
Approximately 1.5 g of tumor tissue was homogenized,
filtered, and centrifuged at 4 °C. Concentrations of
TNFα, IFNγ, and IL-10 in the collected supernatant (ap-
proximately 750 μL) were measured using a mouseELISA kit (Ebioscience, San Diego, CA, USA) according
to the manufacturer’s instructions. The optical density
was measured using a microplate reader at a wavelength
of 450 nm with correction at 570 nm.
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism Software Package (v.5, GraphPad Software, San
Diego, USA). Differences between groups were analyzed
using the unpaired, two-tailed Student’s t test. Mice sur-
vival analysis was performed by generating Kaplan-
Meier survival curves. All data are presented as the
mean ± SEM of at least three experiments. It was consid-
ered that p values less than 0.05 were statistically
significant.
Results
In vitro cytotoxic activity of DpC and Dp44mT relative to
the commercially available chelator, L1, against a panel of
non-tumorigenic, immortalized cell lines and the
neuroblastoma cell line, SK-N-LP
Initial studies examined the selective anti-proliferative
activity of DpC and Dp44mT relative to the well-
characterized and commercially available chelator, L1,
against a panel of non-tumorigenic, immortalized cells
compared to a neuroblastoma cell line (Fig. 2). As deter-
mined by the XTT assay, the agents DpC and Dp44mT
at a relatively high concentration of 25 μM, inhibited the
proliferation and viability of the following immortalized,
non-tumorigenic cell lines as a function of time (24–72 h/
37 °C): human bone marrow-derived, Tert-immortalized
mesenchymal stem cells (MSC), rat cardiomyocytes
(H9C2), a human hepatocyte cell line (MIHA) and human
kidney cells (HK2), as well as the neoplastic, neuroblast-
oma cell line, SK-N-LP (Fig. 2a). On the other hand, L1
(25 μM) was consistently less effective than Dp44mT in
MSC and H9C2 cells, while being markedly less active
than DpC against all cell types. Notably, L1 demonstrated
low activity against the immortalized, non-tumorigenic
cell lines, especially MSC and HK2 cells, but demon-
strated relatively higher activity against neoplastic SK-N-
LP cells (Fig. 2a).
At 25 μM, Dp44mT demonstrated significantly (p <
0.001–0.01) less anti-proliferative activity than DpC in the
panel of non-tumorigenic, immortalized cells (Fig. 2a). In
fact, Dp44mT showed similar anti-proliferative efficacy to
L1 when incubated with the non-tumorigenic, immortal-
ized MIHA and HK2 cells, but was significantly (p <
0.001–0.01) more effective at inhibiting proliferation than
L1 in non-tumorigenic, MSC, and H9C2 cells after 48 or
72 h. Against the neoplastic SK-N-LP cell-type, Dp44mT
and particularly DpC showed significantly (p < 0.001–0.05)
greater anti-proliferative activity than L1 after incubations
of 24–72 h (Fig. 2a).
Fig. 2 DpC has more potent cytotoxic effects than Dp44mT and L1 on a neoplastic, neuroblastoma cell line, SK-N-LP, than a panel of non-
tumorigenic, immortalized cells (i.e., MSC, HSC2, MIHI, HK2). In vitro cellular proliferation was assessed by the XTT assay comparing a panel of
non-tumorigenic, immortalized cells and a neuroblastoma cell line incubated with either DpC, Dp44mT, or L1. a The effect of DpC, Dp44mT,
or L1 (25 μM) on proliferation and viability as a function of time relative to control media alone (24–72 h/37 °C). b The effect of DpC, Dp44mT, or
L1 at concentrations of 2.5, 25, and 250 μM on proliferation and viability relative to control medium alone after a 24 h/37 °C incubation. Data are
presented as mean ± SEM (n = 3)
Table 1 IC50 values (μM) for DpC, Dp44mT, and L1 in MSC,
H9C2, MIHA, HK2, and SK-N-LP cells
DpC Dp44mT L1
MSC 145.23 ± 13.58 227.32 ± 5.04 >250
H9C2 >250 >250 >250
MIHA 165.73 ± 5.81 227.69 ± 9.93 >250
HK2 17.27 ± 0.19 167.08 ± 0.94 >250
SK-N-LP <2.5 249.39 ± 51.03 >250
The MSC, H292, MIHA, HK2, and SK-N-LP cells were incubated for 24 h/37 °C
with either control, DpC, Dp44mT, or L1 (see “Methods”). The IC50 values (μM)
are presented as mean ± standard deviation (n = 3)
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incubation on the panel of non-tumorigenic, immortal-
ized cell lines (i.e., MSC, H9C2, MIHA, and HK2) as a
function of concentration (2.5, 25, or 250 μM), it was
notable that Dp44mT and DpC showed generally similar
anti-proliferative activity (Fig. 2b). However, at 25 μM,
DpC demonstrated significantly (p < 0.001–0.05) greater
efficacy than Dp44mT in all non-tumorigenic cell-types.
Further, at a concentration of 250 μM, these thiosemi-
carbazones were significantly (p < 0.001–0.05) more po-
tent than L1 against all cell lines examined (Fig. 2b).
Assessing the neoplastic SK-N-LP cell line, it was evi-
dent that L1 demonstrated significantly (p < 0.05) greater
activity at 25 and 250 μM than that observed against the
non-tumorigenic, immortalized cell-types. In addition,
both Dp44mT, and particularly DpC, were significantly
(p < 0.01–0.05) more effective against SK-N-LP cells than
L1 at 25 and 250 μM (Fig. 2b).
Regarding the selective anti-proliferative activity of
these agents in neoplastic cells over non-tumorigenic,
immortalized cells, which was observed for Dp44mT and
DpC previously [8, 27, 42], it was notable that DpC,
Dp44mT, and L1 at 2.5 μM showed no pronounced anti-
proliferative activity against the non-tumorigenic,
immortalized cell lines (i.e., MSC, H9C2, MIHA, and
HK2), but was significantly (p < 0.001–0.05) more effect-
ive at inhibiting neoplastic SK-N-LP neuroblastoma cells
(Fig. 2b). In these tumor cells, the activity of DpC at
2.5 μM was markedly and significantly (p < 0.001) greater
than either Dp44mT or L1, demonstrating its greater
potency (Fig. 2b). As the concentration of Dp44mT orDpC was increased to 25 or 250 μM, the selectivity
against the neoplastic SK-N-LP cells relative to the non-
tumorigenic immortalized cells was reduced or lost
(Fig. 2b). This observation indicates the existence of a
“therapeutic window” against the neoplastic cells, which,
when exceeded, results in non-tumorigenic cell cytotox-
icity [44]. Similar therapeutic responses between non-
tumorigenic and neoplastic cells are also generally
observed for other types of cytotoxic chemotherapeutics,
demonstrating the importance of an optimal dose [44].
Table 1 shows the IC50 values calculated for the data
shown in Fig. 2b.
DpC induces greater apoptosis in neuroblastoma cells
than either Dp44mT or L1
Considering the results in Fig. 2a, b demonstrating the
anti-proliferative activity of these agents, studies then in-
vestigated the effect of a 24 h/37 °C incubation with ei-
ther: control medium (Con), control medium containing
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Dp44mT, or L1 (25 μM) on the apoptosis of a panel of
four neuroblastoma cell lines via examining Annexin V/
PI staining by flow cytometry (Fig. 3). The cells were
grouped into (A) live cells (bottom left quadrant; Fig. 3),
(B) necrotic cells (top left quadrant; Fig. 3), (C) those
undergoing early apoptosis (bottom right quadrant;
Fig. 3), or (D) late apoptosis (top right quadrant; Fig. 3)Fig. 3 The effects of Dp44mT, DpC, and L1 on apoptosis in four neuroblas
judged by flow cytometric analysis. Cells were incubated with either control me
L1 (25 μM) for 24 h/37 °C. Apoptosis was examined using Annexin V/PI stainin
were defined as being in late apoptosis, while cells being Annexin V+/PI– (bo
were Annexin V–/PI+ (top left quadrant) were considered to be necrotic and t
The values shown represent the percentage of cells in each quadrant. Resultsbased on the Annexin V/PI staining and expressed as a
percentage of total cells. Notably, quantitation of cells in
each of these groups is presented in the relevant quad-
rant in Fig. 3.
Furthermore, these studies also assessed the ability of
these agents to induce apoptosis in neuroblastoma cells
with and without MYCN overexpression. This was im-
portant as MYCN amplification and its overexpressiontoma cell lines, namely SK-N-LP, BE(2)C, SK-N-AS, and SH-SY5Y, as
dia alone (Con), control media containing DMSO (DMSO), DpC, Dp44mT, or
g by flow cytometry. Cells that were Annexin V+/PI+ (top right quadrant)
ttom right quadrant) were considered to be in early apoptosis. Cells that
hose that were negative for both (bottom left quadrant) were viable cells.
show a typical experiment of three performed
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predictors of poor prognosis in neuroblastoma [45–47].
In the studies in Fig. 3, SK-N-LP and BE(2)C neuro-
blastoma cells, which possess MYCN amplification,
were compared to the SK-N-AS and SH-SY5Y neuro-
blastoma cell lines, which do not possess MYCN
amplification [48].
Most cells after incubation with control medium or
this medium containing DMSO were viable (95.2–
98.6 %; Fig. 3), with only a very low percentage of cells
in late-stage apoptosis (0.022–0.41 %; Fig. 3). Examining
early apoptosis, DpC had similar effects to Dp44mT in
the two MYCN amplified neuroblastoma cell lines, in-
cluding SK-N-LP (35 % of DpC- vs. 38.1 % of Dp44mT-
treated cells in early apoptosis) and BE(2)C 4.36 % of
DpC- vs. 7.09 % of Dp44mT-treated cells in early apop-
tosis). However, when assessing late-stage apoptosis,
DpC was more effective than Dp44mT in SK-N-LP
(27.4 % of DpC- vs. 1.19 % of Dp44mT-treated cells) and
BE(2)C cells (26.7 % of DpC- vs. 9.48 % of Dp44mT-
treated cells; Fig. 3), suggesting a more potent mechan-
ism of action for DpC. Further, DpC displayed greater
activity than Dp44mT in the remaining neuroblastoma
cell lines without MYCN amplification (i.e., SK-N-AS
and SH-SY5Y) in terms of both early and late apoptosis.
Hence, DpC and Dp44mT generally demonstrated
greater activity in neuroblastoma cells with MYCN amp-
lification when compared to those without this alter-
ation. Compared to DpC and Dp44mT, L1 had only very
modest anti-neuroblastoma activity in terms of inducing
apoptosis, with only 0.1–5.31 % of cells in early or late
apoptosis (Fig. 3). Overall, DpC was the most active
agent in inducing apoptosis in the 4 neuroblastoma cell
lines and importantly demonstrated marked activity irre-
spective of MYCN amplification (Fig. 3).
Growth inhibition of orthotopic neuroblastoma in a nude
mouse model after DpC treatment
Considering the marked activity of DpC against neuro-
blastoma cells in vitro (Figs. 2 and 3), studies then pro-
gressed to assess its selective anti-tumor activity in vivo
using nude mice bearing an orthotopic neuroblastoma
in the fat pad of the left adrenal gland (Fig. 4a–c). This
model has been used previously to assess the anti-
neuroblastoma activity of other potential chemothera-
peutics [49, 50]. In these studies, groups of mice (n = 4)
underwent daily intravenous injection with the vehicle
control or DpC (4 mg/kg) for 3 weeks and tolerated this
intensive treatment routine well. At the end of the study,
the mice were then sacrificed for tumor size comparison.
Notably, the 3-week treatment period was the maximum
that could be utilized due to the rapid growth of the
tumor in the control group, which necessitates euthan-
asia to satisfy the pre-set, local ethical requirements.Post-mortem neuroblastoma xenografts showed a sig-
nificant (p < 0.05) decrease of the in vivo tumor im-
aging ROI value (Fig. 4b) and also the tumor volume
in the DpC-treated mice relative to the vehicle-treated
control (Fig. 4c).
No surface temperature fluctuations of the mice were
found post-DpC administration during the entire treat-
ment period (data not shown). Although mouse body
weights in the DpC-treated group did not show a dis-
tinct decline, their weight gain within the 3-week treat-
ment period showed a slight, but significant (p < 0.05)
decrease relative to that of the control group (Fig. 4d).
The slight reduction in weight gain in mice treated with
DpC is in contrast to previous studies, where similar
treatment regimens did not significantly (p > 0.05) affect
animal weight [26]. The reason for the slight difference
between these investigations could be the more intensive
treatment regime in the current study, where the ani-
mals were given DpC every day for 3 weeks. This is in
contrast to the previous study, where the mouse was
treated for 5 days/week with 2 days of rest before under-
going the next cycle of treatment [26].
Evaluation of the therapeutic effect of DpC in the
orthotopic neuroblastoma mouse model
In DpC-treated mice relative to the control, significantly
(p < 0.05) higher levels of Annexin V (+)/PI (+) cells and
caspase 3 were demonstrated in tumor tissues post-
mortem (Fig. 5a). Indeed, assessment of the percentage
of live tumor cells in the controls (97.1 %) was far
greater than in the DpC-treated group (50.9 %), with a
marked increase in the percentage of tumor cells in
early- or late-stage apoptosis after DpC treatment
(28.2 and 14.2 %, respectively) relative to the control
group (0.59 and 1.15 %, respectively). These results
clearly demonstrated the marked anti-neuroblastoma
activity of DpC.
In contrast, upon examining normal tissues, e.g., the
lung (Fig. 5b), no evidence of significantly increased
Annexin V (+)/PI (+) cells or caspase 3 was observed.
Flow cytometric examination of the percentage of viable
cells in the lungs of the controls (99.5 %) was similar
(p > 0.05) to the DpC-treated group (95.9 %), there being
a small increase in the percentage of lung cells in late-
stage apoptosis after DpC treatment (0.2 %) relative to
the control group (0.017 %; Fig. 5b). Similarly, no
marked alterations in these parameters were also ob-
served in a variety of other normal tissues (i.e., spleen,
heart, kidney, and brain; data not shown). However, sig-
nificant neuroblastoma xenograft regression was con-
firmed by H&E staining (Fig. 5c). Histopathological
examination of H&E-stained sections of the lungs
suggested some evidence of exudative inflammation
(Fig. 5d), while cellular morphology remained normal in
Fig. 4 Treatment with intravenous (tail vein) DpC (4 mg/kg/day) over 3 weeks significantly reduces orthotopic neuroblastoma tumor growth (in
adrenal gland) in vivo using SK-N-LP/Luciferase xenografts in nude mice. a Upper panel mice are shown before administration via the tail vein of
the vehicle control (Con) or DpC (Day 0), while the lower panel represents mice treated intravenously (tail vein) with either DpC (4 mg/kg/day)
or the vehicle control daily for 3 weeks (i.e., Day 21). b DpC-treated tumors had significantly (p < 0.05) lower region of interest (ROI) change rates
when compared to vehicle control tumors. c Neuroblastoma xenografts significantly decreased in volume after the DpC treatment in (a). d Body
weight change (%) of mice treated with the control (vehicle) or DpC (4 mg/kg/day) over 3 weeks. *p < 0.05 by an unpaired two-tailed t test. The
results are presented as mean ± SEM (n = 4)
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The alterations observed in the lung with DpC treat-
ment were not reported in a previous study with this
agent in another in vivo tumor model [26]. Again, this
may indicate that the more intensive treatment regimen
used in the current experiments was outside the thera-
peutic window and led to some limited adverse effects
on the lungs.
Mechanism of the anti-neuroblastoma activity of DpC and
Dp44mT
Considering the marked anti-neuroblastoma activity of
DpC and Dp44mT in vitro (Figs. 2 and 3) and the in vivo
efficacy of DpC in the mouse neuroblastoma model
(Fig. 4), studies then examined the mechanism of this
activity. As iron chelation plays a role in the anti-
proliferative activity of the DpT analogues [7, 8, 27], itwas of interest to examine the effect of these compounds
on heme-containing proteins, particularly those that
could play an integral role in cellular metabolism.
Both cytoglobin (Cygb) and neuroglobin (Ngb) are
intracellular globins (belonging to the same family as
hemoglobin and myoglobin) containing the crucial heme
prosthetic group that contains iron [51, 52]. These
heme-containing globins have been reported to facilitate
the diffusion of oxygen in tissues and also act as oxygen
sensors and radical scavengers [51, 52]. The overexpres-
sion of both these proteins is found in hypoxia or under
oxidative stress [52]. The effects of chelators on Cygb
and Ngb in non-tumorigenic, immortalized cells relative
to neuroblastoma cells remains unknown, and it was con-
sidered important to assess the effects of DpC and
Dp44mT on these proteins. Indeed, their iron-containing
heme groups could be indirectly affected by chelation of
Fig. 5 a Flow cytometric analysis demonstrates that treatment of nude mice bearing an orthotopic neuroblastoma xenograft with intravenous
DpC (4 mg/kg/day) administered via the tail vein over 3 weeks increases Annexin V and caspase 3 expression in the tumor, but not in b the lung. *p < 0.05
by an unpaired two-tailed Student’s t test in three nude mice after 21 days of DpC treatment. c, d Histopathological assessment (hematoxylin and eosin,
H&E) of the tumor (c) and lung (d) after 3 weeks of intravenous treatment of mice with either the vehicle control or DpC (4 mg/kg/day). c H&E staining
demonstrating a decrease in tumor cell infiltration after DpC treatment relative to the vehicle control and d evidence of exudative inflammation could be
observed in lung tissue of nude mice following treatment with DpC relative to the control. The results in (a) and (b) are typical experiments from three
performed. The results in (c) and (d) are typical photographs from sections of tissue. Scale bar on H&E photographs, 50 μm
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which may result in inhibition of protein function.
Interestingly, flow cytometric analysis demonstrated that
DpC significantly (p < 0.05) upregulated Cygb and Ngb ex-
pression in HK2 kidney cells and SK-N-LP neuroblastoma
cells after an incubation with DpC (25 μM) for 24 h/37 °C
(Fig. 6a). A less marked increase in Ngb expression was also
observed in both HK2 and SK-N-LP cells after a 12 h/37 °C
incubation (Fig. 6a). In contrast, Cygb and Ngb expression
slightly decreased in MSC and H9C2 cells after incubation
with DpC. However, unlike DpC, Dp44mT failed to signifi-
cantly induce similar alterations in Cygb and Ngb expres-
sion in all cell lines tested, apart from a slight, but notsignificant (p > 0.05) increase in Ngb in the SK-N-LP cells
(Fig. 6a). These results were also reflected in western blot
studies using SK-N-LP cells, where DpC mediated a signifi-
cant (p < 0.05) increase in both Cygb and Ngb expression
levels, while Dp44mT only significantly (p < 0.05) affected
Ngb expression (Fig. 6b). These observations suggested a
difference in the mechanism of action of these two agents
despite their similar structures (Fig. 1b, c).
Effect of DpC and Dp44mT on key molecular pathways in
neuroblastoma
Considering that DpC and Dp44mT promote apoptosis
in neuroblastoma cells (Figs. 3 and 5), further studies
Fig. 6 a Incubation of DpC (25 μM) with SK-N-LP neuroblastoma cells and HK2 non-tumorigenic, immortalized kidney cells induces Cygb and
Ngb expression after a 24-h incubation. In these studies, non-tumorigenic, immortalized cell lines (i.e., MSC, H9c2, or HK2), or neoplastic, neuro-
blastoma (SK-N-LP) cells, were incubated for either 0, 12 or 24 h/37 °C with either control medium (Con; no agent added), Dp44mT (25 μM), or
DpC (25 μM) and then flow cytometric analysis performed using Flow Jo 8.8.2. Black, red, and blue lines represent the control, or the cells treated
with the iron chelators for 12 and 24 h, respectively. Results shown are typical experiments of three performed. b Western blot analysis of Cygb
and Ngb expression in SK-N-LP cells following incubation with control media (Con), Dp44mT (25 μM), or DpC (25 μM) for 24 h/37 °C. The bands
presented in the blots are representative of three repeats and the lanes have been cropped from raw data images containing all three repeats
(raw data shown in Additional File 1) for clarity (lanes separated by dotted lines). Densitometry data in (b) are presented as the mean ± SEM
(n = 3). *p < 0.05 by an unpaired two-tailed Student’s t test in triplicate experiments
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by examining the key molecular pathways that initiate
apoptosis in neuroblastoma cells, including the NF-ĸB
and MAPK signaling cascades. Notably, both NF-ĸB and
MAPK pathways, via their activation of p38 and JNK,
lead to transcription of genes that promote apoptosis,
namely TNFα, c-Jun, AP-1, cytochrome c, etc. [53, 54].
Further, these pathways also promote cleavage of caspase
8 and 9, which ultimately leads to caspase 3 cleavage
and apoptosis [55]. Hence, western blot studies assessed
the effects of DpC and Dp44mT on the expression of a
key inhibitor of the NF-ĸB pathway, namely IĸBα [56],
as well as the major regulator of MAPK signaling, that is
JNK, and down-stream targets of these signaling path-
ways, including cleaved caspase 3 and 9 (Fig. 7).Examining the NF-ĸB pathway, a significant (p < 0.01–
0.001) decrease in IĸBα expression was observed after
incubation with Dp44mT or DpC (Fig. 7a). Considering
that IkBα inhibits NF-ĸB nuclear localization and func-
tion [56], a decrease in IĸBα expression will enable NF-
ĸB activation. Further, a significant (p < 0.05–0.001)
increase in cleaved caspase 3 and 9 was observed upon
incubation with either DpC or Dp44mT (Fig. 7a). DpC
also significantly (p < 0.05) increased the phosphorylated
JNK/total JNK ratio, while having no significant (p >
0.05) effect on total JNK levels (Fig. 7a). These results
indicate that Dp44mT may activate the NF-ĸB pathway
and also the cleavage of caspase 3 and 9, while DpC acti-
vates both the NF-ĸB and MAPK pathways to promote
apoptosis.
Fig. 7 Molecular mechanisms involved in the DpC-mediated anti-neuroblastoma activity. a Western analysis demonstrating that incubation of SK-
N-LP neuroblastoma cells with either Dp44mT or DpC (25 μM) for 24 h/37 °C significantly: (i) reduced IĸBα levels, (ii) increased cleaved caspase 9
levels, and (iii) increased cleaved caspase 3 levels. DpC also significantly increased the phosphorylated JNK (p-JNK)/total JNK (t-JNK) ratio. Western
blotting was performed as described in the “Methods.” The bands presented are representative of three repeats and have been cropped from raw data
images containing all three repeats (shown in Additional file 1) for clarity (blots separated by dotted lines). b The cytotoxic effects of (i) DpC and (ii)
Dp44mT on SK-N-LP cells are significantly reduced upon inhibition of the JNK, NF-ĸB or caspase (Cas) pathways, while inhibition of p38 signaling only
reduced DpC cytotoxicity. SK-N-LP cells were pre-incubated for 2 h/37 °C with ERK1, p38, JNK, NF-ĸB, or Cas inhibitors prior to incubation with either DpC
(25 μM) or Dp44mT (25 μM) in the presence or absence of these inhibitors for 24 h/37 °C. Cell viability was assessed using the XTT assay, as described in
the “Methods.” c Significantly higher levels of secreted (i) TNFα were detected in the xenografts of the DpC-treated mice (p< 0.05), while no significant
changes in (ii) IFNγ or (iii) IL-10 secretion were detected. The levels of these cytokines were quantified via the ELISA assay, as described in the “Methods.”
Data in graphs is presented as the mean ± SEM (n= 3). *p< 0.05; **p< 0.01; ***p< 0.001, as determined by an unpaired Student’s two-tailed t test
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ther investigate the role of the MAPK/NF-ĸB/caspase
signaling pathway in the anti-proliferative activity ob-
served with DpC, selective inhibitors of these pathways
were utilized to assess the mechanism of the cytotoxicity
of DpC (25 μM) or Dp44mT (25 μM; Fig. 7b). In thesestudies, a 2 h/37 °C pre-incubation of SK-N-LP neuro-
blastoma cells with p38, JNK, NF-ĸB, and caspase inhibi-
tors prior to a 24 h/37 °C incubation with DpC and the
inhibitors could slightly, but significantly (p < 0.001-
0.05), reduce the cytotoxicity of DpC, while the ERK in-
hibitor did not have any significant (p > 0.05) effect
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tors could slightly and significantly (p < 0.001–0.05) de-
crease the cytotoxicity of Dp44mT, while the ERK and
p38 inhibitors did not have a significant (p > 0.05) effect
(Fig. 7b). For both DpC and Dp44mT, the caspase
inhibitor was the most effective at inhibiting their cyto-
toxicity, suggesting the important role of caspases in
DpC/Dp44mT-mediated apoptosis.
To further investigate the mechanism of action of
DpC, in vivo studies were performed to assess its effects
on TNFα, IFNγ, and IL-10 levels, as these are down-
stream targets of the MAPK/NF-ĸB/caspase signaling
pathways [56, 57]. Considering the activation of these
pathways in vitro in neuroblastoma cells by DpC (Fig. 7a,
b), they could also be potentially activated by DpC
in vivo. Interestingly, significantly (p < 0.05) higher TNFα
levels were detected by ELISA assays in SK-N-LP tumor
xenografts of the DpC-treated group (Fig. 7 Ci). Further,
IFNγ and IL-10 were slightly increased or decreased in
these xenografts, respectively, although these effects
were not significant (p > 0.05) (Fig. 7Cii, iii).
Discussion
The importance of the DpT series of analogues as new
anti-cancer therapeutics is demonstrated by (1) their
broad and selective anti-tumor activity [7, 8, 26, 27], (2)
their ability to inhibit metastasis via up-regulation of
NDRG1 or 2 [22–24], and (3) the efficacy of these com-
pounds to overcome Pgp-mediated drug resistance [10,
12, 13]. In fact, in early 2016, DpC entered multi-center
clinical trials for the treatment of advanced and resistant
tumors (NCT02688101).
Considering the marked anti-tumor activity of the DpT
analogues, their activity and mechanism of action was
examined against the belligerent childhood tumor, neuro-
blastoma, in vitro and in vivo. The current studies have
demonstrated in vitro that the commercially available che-
lator, L1, was markedly less effective than Dp44mT, and
particularly DpC, in terms of its activity against neuro-
blastoma cells. This is probably because L1 does not form
cytotoxic redox-active metal complexes upon saturation
of its coordination sphere with iron (i.e., (L1)3Fe
III), since
its iron ligating sites are “hard” oxygen donors (Fig. 1d)
which prevents redox cycling [58, 59]. This is in contrast
to both Dp44mT and DpC, where “soft” N and S donors
(Fig. 1b, c) in the coordination sphere enable the gener-
ation of redox-active metal complexes [8, 13, 42] that play
an important role in the induction of apoptosis [9–12].
Hence, for L1, its major mechanism of action is confined
to essential metal-binding and depletion that results in the
inhibition of proliferation (a “single punch”), while
Dp44mT and DpC act via binding essential metals and
then redox cycling to generate a “double punch” to inhibit
tumor growth [1, 8, 13, 42].Importantly, in terms of the selectivity of these agents,
a therapeutic window was observed in vitro at low
concentrations where DpC and Dp44mT showed no
anti-proliferative activity against the panel of non-
tumorigenic, immortalized cells (i.e., MSC, H9C2,
MIHA, and HK2), but did inhibit the neoplastic, neuro-
blastoma cell line, SK-N-LP (Fig. 2b). This was in good
agreement with previous studies in other tumor cell
types in vitro, where selective anti-cancer activity and a
therapeutic window was observed for Dp44mT and DpC
[7, 8, 26, 27]. Moreover, the marked anti-tumor activity
of DpC was independent of MYCN amplification, which
is a key oncogene and prognostic indicator in neuro-
blastoma [45–47]. It was also of interest that Dp44mT
demonstrated relatively higher efficacy against MYCN
amplified cell lines relative to neuroblastoma cells with-
out MYCN amplification.
The studies demonstrating the marked and selective
anti-neuroblastoma efficacy of DpC in vitro were con-
firmed in vivo, where this agent decreased neuroblast-
oma growth without major toxicology. Furthermore,
mouse body weights in the DpC-treated group did not
show a distinct decline relative to the vehicle control in
concordance with prior reports [26, 27], although there
was a slight decrease in weight gain in the DpC-treated
group. However, in contrast to a previous investigation
using a less intensive dosing schedule [26], DpC was
shown to induce lung inflammation (Fig. 5d). This effect
may be due to the more intensive treatment regimen im-
plemented herein (i.e., 7 days/week vs. 5 days/week with
2 days rest used previously) and indicates that careful
titration of the dose is required to ensure appropriate
anti-cancer activity without toxic effects.
In terms of the decreased neuroblastoma growth ob-
served in vivo, it is notable that the effect of DpC on the
tumor was not merely cytostatic, but cytotoxic, as there
was significantly elevated caspase 3 and Annexin V
(+)/PI (+) staining in the tumor after DpC treatment, in-
dicating increased apoptosis. Such cytotoxicity within
the neuroblastoma tumor was important to demonstrate,
as the induction of cytostasis is of little benefit to pa-
tients, particularly when drug administration is stopped,
since it leads to tumor rebound.
Considering the mechanism of action of the DpT ana-
logues and the role of iron in their activity [7, 8, 27], it
was of interest to examine the effect of the agents on
heme-containing proteins, particularly those that play a
role in metabolism. While chelators do not directly
remove iron from heme itself, they could affect iron
trafficking pathways subsequent to its incorporation into
heme. Both Cygb and Ngb are intracellular heme-
containing proteins of the globin family that play roles
in oxygen metabolism and appear to act as reactive
oxygen species scavengers [60–63]. DpC significantly
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and SK-N-LP neuroblastoma cells (Fig 6a, b), while
Dp44mT only increased Ngb levels (Fig. 6a, b). There
has been little work to assess the role of iron-depletion
on the expression of either Cygb or Ngb, but a study
in rats demonstrated that a low iron diet reduced
Ngb levels [64]. Considering this, it can be suggested
that the ability of DpC and Dp44mT to chelate iron
is not the cause of the increase in Ngb expression
(Fig. 6). In contrast, since Cygb expression occurs
under oxidative stress [65], it can be speculated that
the potent oxidative stress induced by DpC metal
complexes [13] may be involved in increasing Cygb
and Ngb expression. Thus, the increase in Ngb and
Cygb levels after incubation with DpC may represent
a protective response. However, it is unclear why
Dp44mT, which is also redox active and has a similar
mechanism of cytotoxic activity to DpC [9–13, 42],
did not increase Cygb expression.
As part of their complex mechanism of action, previous
studies have indicated that Dp44mT and DpC haveFig. 8 Overview of the potential mechanisms involved in the DpC-media
neuroblastoma cells, which may (1) activate cytotoxic T cells to destroy tu
down-stream signaling pathways. These include the MAPK/p38/JNK and N
numerous genes, including those that induce apoptosis, as well as cytoki
caspase 8, leading to caspase 3 cleavage and subsequent apoptosis. Mor
reactive oxygen species (ROS) [13]. The generation of ROS triggers the re
caspase 9, which then also cleaves caspase 3, leading to apoptosis. Furth
and cytoglobin (Cygb) expression as both of these proteins respond to o
apoptosis, could contribute to the anti-cancer activity of DpC in neuroblamarked effects on multiple signaling pathways in other
tumor types [15–21]. Significantly, the current study also
demonstrated that DpC increased the levels of phosphor-
ylated JNK and cleaved caspase 3 and 9, while it de-
creased IkBα expression (an inhibitory factor of NF-ĸB
signaling; [56]) in neuroblastoma cells in vitro. In con-
trast, Dp44mT was less effective and only mediated an
increase in cleaved caspase 3 and 9 and a decrease in
IkBα expression, while not significantly affecting phos-
phorylated JNK.
Importantly, the ability of DpC to increase TNFα ex-
pression in neuroblastoma tumors in vivo may poten-
tially contribute to these pro-apoptotic signaling effects
shown in vitro, as TNFα binds to the TNFα receptor
(TNFR) to activate the MAPK/p38/JNK and NF-ĸB sig-
naling cascades, which lead to nuclear transcription of
genes that induce apoptosis (Fig. 8) [66]. Further, the
redox activity of DpC [13, 67] may also promote the re-
lease of cytochrome c from mitochondria (as found for
Dp44mT; [8]), which mediates the cleavage of caspase 9,
leading to apoptosis [8] (Fig. 8).ted effects on neuroblastoma. DpC increases TNFα expression in
mor cells and/or (2) acts on the TNFα receptor (TNFR) to activate
F-ĸB signaling cascades, which lead to nuclear transcription of
nes such as TNFα. Activation of TNFR also promotes cleavage of
eover, DpC is also highly redox active, resulting in the production of
lease of cytochrome c from mitochondria [8], leading to cleavage of
er, the increased ROS also leads to upregulation of neuroglobin (Ngb)
xidative stress. Together, these molecular effects, which promote
stoma
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ing are closely linked to cancer development [68, 69]
and are involved in integrating oncogenic signaling [33,
70]. Studies in vitro with inhibitors of p38, JNK, NF-ĸB,
and caspases suggested their involvement in terms of the
mechanism of action of DpC against neuroblastoma
(Fig. 8). However, while these inhibitors did reduce the
anti-proliferative efficacy of DpC, they were not mark-
edly effective and did not totally inhibit its activity. This
observation suggests the mechanism of action of DpC in
neuroblastoma is via their activity on multiple molecular
targets (Fig. 8) and underlines the importance of poly-
pharmacology in their marked activity [28].
Finally, considering the potential effects of DpC on the
immune system, it is of note that TNFα levels were signifi-
cantly increased in vivo in neuroblastoma xenografts post-
DpC treatment (Fig. 7 Ci). This finding was associated
with a slight, but not significant, increase in IFNγ and de-
crease in IL-10. Notably, TNFα, together with IFNγ, plays
an important role in initiating the immune response by
activating tumor-specific cytotoxic T cells [66]. Hence, the
ability of DpC to increase TNFα in tumors could promote
the endogenous immune response to mediate immune
cell infiltration of the cancer. Such an immune response
could also be potentially implicated in the ability of DpC
to inhibit neuroblastoma growth in vivo.
Conclusions
In conclusion, DpC demonstrated a potent cytotoxic pro-
file against neuroblastoma cells with or without MYCN
amplification in vitro and was demonstrated to effectively
inhibit orthotopic neuroblastoma xenograft growth in vivo
without causing marked toxicity. In terms of its molecular
mechanism of action against neuroblastoma tumors, DpC
significantly increased levels of phosphorylated JNK, neu-
roglobin, cytoglobin, and cleaved caspase 3 and 9, while
simultaneously decreasing inhibitory IĸBα levels in vitro
(Fig. 8). Together, these results suggest that DpC may have
a promising role in neuroblastoma treatment.
Additional file
Additional file 1: Figure S1. Raw Western blot images of Ngb, Cygb, IĸBα,
cleaved caspase 9 and 3, phosphorylated JNK (p-JNK) and total JNK
(t-JNK) expression relative to the loading control, β-actin, in human
SK-N-LP neuroblastoma cells following incubation with DpC (25 μM; Lanes
1-3), control medium (Lanes 4-6) or Dp44mT (25 μM; Lanes 7-9) for 24 h/37oC.




Cygb: Cytoglobin; DCF: Dichlorofluorescein; DFO: Desferrioxamine;
DMSO: Dimethyl sulfoxide; DpC: Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-
thiosemicarbazone; Dp44mT: Di-2-pyridylketone 4,4-dimethyl-3-
thiosemicarbazone; ELISA: Enzyme-linked immunosorbent assay; H &
E: Hematoxylin-eosin; IHC: Immunohistochemistry; IFNγ: Interferon gamma;IL-10: Interleukin 10; IVIS 100: In vivo imaging system Xenogen 100;
IkBα: Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor alpha; L1: Deferiprone; MSC: Mesenchymal stem cell;
Ngb: Neuroglobin; NDRG1: N-myc downstream regulated gene-1; NF-
kB: Nuclear factor kappa B; PBS: Phosphate-buffered saline; ROS: Reactive
oxygen species; TNFα: Tumor necrosis factor alpha; TNFR: Tumor necrosis
factor receptor
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